Milestone Pharmaceuticals Reports First Product Revenue, Secures $75M Royalty Financing, and Establishes New ATM Program

summarizeSummary

Milestone Pharmaceuticals reported its first product revenue, secured $75 million in royalty financing, and established a new ATM program, significantly improving its liquidity and extending its cash runway to over 12 months.

check_boxKey Events

• First Product Revenue Reported

  The company reported its first product revenue of $0.2 million from U.S. sales of CARDAMYST for the three months ended March 31, 2026, marking its transition to a commercial-stage company.

• Secured $75 Million Royalty Financing

  Milestone Pharmaceuticals closed a royalty financing arrangement on January 12, 2026, receiving $75.0 million in exchange for tiered quarterly royalty payments on U.S. net sales of CARDAMYST, with an effective interest rate of 19.6%.

• New At-The-Market (ATM) Offering Program Established

  On May 13, 2026, the company entered into a new Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell common shares from time to time, replacing a previous ATM program terminated on March 6, 2026.

• Strong Liquidity and Cash Runway

  The company ended the quarter with $184.2 million in cash, cash equivalents, and short-term investments, projecting a cash runway of at least 12 months from the filing date.

auto_awesomeAnalysis

Milestone Pharmaceuticals has significantly strengthened its financial position, reporting its first product revenue from CARDAMYST sales and securing substantial capital through a $75.0 million royalty financing arrangement. This, combined with proceeds from an ATM program and warrant exercises, has boosted the company's cash reserves to $184.2 million, providing a projected cash runway of at least 12 months. The company also initiated a new ATM program for future capital raises. While net losses increased due to higher commercialization expenses for CARDAMYST, these investments are critical for the product's market penetration and the advancement of its pipeline, including a new Phase 3 study for AFib-RVR.